ATC code L

Pharmaceutical drug classification
ATC code L: Antineoplastic and immunomodulating agents
  • L01 Antineoplastic agents
  • L02 Endocrine therapy
  • L03 Immunostimulants
  • L04 Immunosuppressants
Other ATC codes
  • A
  • B
  • C
  • D
  • G
  • H
  • QI
  • J
  • L
  • M
  • N
  • P
  • R
  • S
  • V

ATC code L Antineoplastic and immunomodulating agents is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3][4]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

References

  1. ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
  2. ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
  3. ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
  4. ^ "ATC/DDD Index 2022: code L". WHO Collaborating Centre for Drug Statistics Methodology.
  5. ^ "ATCvet Index 2022: code QL". WHO Collaborating Centre for Drug Statistics Methodology.
  • v
  • t
  • e
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System
gastrointestinal tract
/ metabolism (A)blood and blood
forming organs (B)cardiovascular
system (C)skin (D)genitourinary
system (G)endocrine
system (H)infections and
infestations (J, P, QI)malignant disease
(L01–L02)immune disease
(L03–L04)muscles, bones,
and joints (M)brain and
nervous system (N)respiratory
system (R)sensory organs (S)other ATC (V)
  •  Drugs
  • Pharmacological classification systems
  • ATC codes
  •  Medicine portal
  • v
  • t
  • e
SPs/MIs
(M phase)
Block microtubule assembly
Block microtubule disassembly
DNA replication
inhibitor
DNA precursors/
antimetabolites
(S phase)
Folic acid
Purine
Pyrimidine
Deoxyribonucleotide
Topoisomerase inhibitors
(S phase)
I
II
II+Intercalation
Crosslinking of DNA
(CCNS)
Alkylating
Platinum-based
Nonclassical
Intercalation
Photosensitizers/PDT
Other
Enzyme inhibitors
Receptor antagonists
Other/ungrouped
  • v
  • t
  • e
CI monoclonal antibodies ("-mab")
Receptor tyrosine kinase
Others for solid tumors
Leukemia/lymphoma
Other
Tyrosine kinase inhibitors ("-nib")
Receptor tyrosine kinase
Non-receptor
Other
  • v
  • t
  • e
Endogenous
Cytokines
Colony-stimulating factors
Interferons
Interleukins
Other protein / peptide
Other
Exogenous
  • v
  • t
  • e
Intracellular
(initiation)
Antimetabolites
Macrolides/
other IL-2 inhibitors
IMiDs
Intracellular
(reception)
IL-1 receptor antagonists
mTOR
Extracellular
Antibodies
Monoclonal
Serum target
(noncellular)
Cellular
target
Unsorted
Polyclonal
-cept (Fusion)
Unsorted